Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU-002 Platform Trial for Primary Prevention of Dominantly Inherited Alzheimer's Disease
NCT05552157Phase 3Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2024
- Primary completion
- Mar 2034
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of remternetug in Alzheimer's disease (AD), sponsored by Washington University School of Medicine. Started Nov 2024; status: recruiting.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05552157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552157.